Meiji Seika Pharma opens a new office in the Boston area to pursue investment opportunities in innovative drugs and technologies
Leading Japanese pharmaceutical business Meiji Seika Pharma Co., Ltd., which specializes in vaccines, hematology, and infectious illnesses, stated today that it has expanded its operations to include a new office in the Boston region and is now making venture investments in the life sciences and healthcare sectors. Meiji Seika Pharma is committed to innovation and global health, as seen by its investments, which are aimed at helping patients worldwide by meeting their unmet medical needs and discovering and developing breakthrough medications.
Meiji Seika Pharma will investigate venture investments in the epicenter of innovation in addition to establishing a new office to increase its footprint in the Boston region. The new office will act as a strategic hub to support investment possibilities that complement Meiji Seika Pharma's existing development and innovation ambition. It will be situated at CIC Cambridge, One Broadway, Cambridge, MA 02142. Meiji Seika Pharma plans to invest in venture capital firms and start-ups that specialize in cutting-edge platform technologies and medication research
